Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Combined Modality Therapy For Locally Advanced Rectal Cancer
NCT00081289Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Mar 2004
- Primary completion
- May 2011
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and oxaliplatin in rectal cancer (2 arms), sponsored by NRG Oncology. Primary endpoint: Pathologic Complete Response Rate. Started Mar 2004; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00081289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081289.